摘要
目的:探究苯磺酸氨氯地平与美托洛尔联合应用治疗高血压合并心力衰竭患者的效果。方法:本研究收集了2020年1月—2021年3月我院收治的120例高血压心力衰竭患者为研究对象,按照随机数字表法的原则进行分组。应用美托洛尔治疗的60例患者作为对照组,联合应用苯磺酸氨氯地平与美托洛尔治疗的60例患者作为研究组。评价两组临床疗效,测定治疗前后心功能指标以及血清白细胞介素(IL)-1、IL-6、肿瘤坏死因子(TNF)-α水平变化。结果:治疗组的总有效率较对照组的显著更高(93.33%VS 80.00%,P<0.05)。治疗后,两组LVEF升高,LVEDD及LVESD降低(P<0.05);治疗后,研究组LVEF高于对照组,LVEDD及LVESD低于对照组(P<0.05)。治疗后,两组血清IL-1、IL-6、TNF-α水平降低(P<0.05);治疗后,研究组血清IL-1、IL-6、TNF-α水平低于对照组(P<0.05)。结论:苯磺酸氨氯地平与美托洛尔联合应用治疗高血压合并心力衰竭患者的效果满意,患者心功能得到改善,血清炎症因子水平降低,值得进行大力临床推广。
Objective:To investigate the effect of amlodipine besylate combined with metoprolol in the treatment of hypertension with heart failure.Method:In this study,120 patients with hypertension and heart failure admitted to our hospital from January 2020 to March 2021 were collected as research objects,and were grouped according to the principle of random number table.60 patients were treated with metoprolol as the control group,and 60 patients were treated with amlodipine besylate and metoprolol as the study group.To evaluate the clinical efficacy of the two groups,and to determine the indexes of cardiac function,serum interleukin-1(IL-1),interleukin-6(IL-6),and tumor necrosis factor(TNF)before and after treatment-αHorizontal variation.Result:The total effective rate of the treatment group was significantly higher than that of the control group(93.33%VS 80.00%,P<0.05).After treatment,LVEF increased,LVEDD and LVESD decreased in both groups(P<0.05);After treatment,LVEF in the study group was higher than that in the control group,LVEDD and LVESD were lower than those in the control group(P<0.05).After treatment,serum IL-1、IL-6、TNF in both groups-αThe level decreased(P<0.05);After treatment,serum IL-1、IL-6、TNF in the study group-αThe level was lower than that of the control group(P<0.05).Conclusion:Amlodipine besylate combined with metoprolol in the treatment of hypertension patients with heart failure has a satisfactory effect,the patients’cardiac function has been improved,and the level of serum inflammatory factors has decreased,which is worthy of great clinical promotion.
作者
徐华
Xu Hua(General Medicine Department of Yingkou Central Hospital,Yingkou Liaoning 117000)
出处
《黑龙江医药》
CAS
2022年第6期1298-1301,共4页
Heilongjiang Medicine journal